The somatostatin analogue, TT-232 inhibits cell proliferation and induces apoptosis in a variety of tumor cells both in vivo and in vitro. While the early transient activation of Erk/MAPK was found to be important for the induction of cell cycle arrest, the signaling pathway leading to the activation of Erk/MAPK had not been fully established. Here we present evidence that activation of the Erk/MAPK pathway by TT-232 involves PI 3-kinase, PKC␦ and the protein tyrosine phosphatase ␣ (PTP␣). We show a physical interaction of PI 3-kinase and PKC␦ with PTP␣ and show that the tyrosine phosphatase plays a role in the activation of MAPK. In this process, PTP␣ Ser-180 and Ser-204 phosphorylation is critical for the induction of phosphatase activity, which is required for dephosphorylation of pp60 c-src . Taken together, we demonstrate the physical and functional association between PI 3-kinase, PKC␦ and PTP␣ in a signaling complex that mediates the antitumor activity of the somatostatin analogue
Somatostatin is a natural tetradecapeptide that was originally discovered and characterized as a hypothalamic inhibitor of pituitary growth hormone release (1) . It inhibits secretion of insulin, glucagon, gastrin and secretin (2) , and has also been identified as an important endogenous antiproliferative agent (3) (4) (5) . To understand the molecular events leading to the inhibition of cell proliferation, the signaling events activated by somatostatin and its analogues have already been investigated. It has been shown that these peptides cause rapid stimulation of tyrosine phosphatases (PTPs), and induce the dephosphorylation of phosphorylated epidermal growth factor receptor (EGFR; 3, 5) . Moreover, recent reports pointed out that somatostatin can inhibit cell proliferation via the activation of tyrosine phosphatases and the induction of cyclindependent kinase inhibitors (CKI) p21
Cip1/Waf1 and p27
Zip1 (6, 7) . Furthermore, somatostatin was found to induce apoptosis in a variety of tumor cell lines (8, 9) .
TT-232 is a somatostatin analogue with a cyclopenta-ring structure: D-Phe-Cys-Tyr-D-Thr-Lys-CysThr-NH 2 . It causes a strong antiproliferative effect both in vivo and in vitro and induced apoptosis in tumor cells (10 -13) . Unlike somatostatin, TT-232 did not inhibit growth hormone release or gastrin secretion in vivo. Due to its antitumor effects, TT-232 is presently under phase II clinical trials as a drug against various types of cancer.
The binding of TT-232 to somatostatin receptor subtypes 1 and 5 has been shown in vitro (Jiang, J., unpublished results) suggesting a receptor mediated signaling mechanism. We could show that several elements are common in TT-232 and somatostatin signaling through SSTR 1. These include the rapid activation of protein tyrosine phosphatases (14) and the induction of cell cycle arrest. This antiproliferative activity is mediated through a signaling pathway involving PKC␦, c-Src kinase and MAP-kinase (15) .
PTP␣ is a ubiquitously expressed receptor-like protein tyrosine phosphatase (RPTP) that has a single membrane spanning region and two cytoplasmic catalytic PTP domains (16) . The cytoplasmic part of PTP␣ is subjected to both tyrosine phosphorylation (17) and serine phosphorylation upon stimulation with the PKC activator TPA (18) . The extracellular part of PTP␣ is heavily glycosylated but, unlike other RPTPs involved in cell-cell or cell-matrix adhesion events, PTP␣ lacks immunoglobulin-like or type III fibronectin domains. A functional ligand of PTP␣ has not yet been identified, which suggests that intracellular signaling pathways significantly contribute to the regulation of PTP␣ (19) . Previously identified substrates for PTP␣ include several proteins of the c-Src family kinases (20, 21) and the insulin receptor (22, 23) .
In this report, we investigated the activation of c-Src by PKC␦ in the antiproliferative signaling mechanism of TT-232, and we show the involvement of PTP␣. We also present evidence that TT-232 induces the physical and functional interaction between PI 3-kinase, PTP␣ and PKC␦. We demonstrate that the activation of PI 3-kinase and PKCs lead to the stimulation of PTP␣ activity and the activation of a downstream signaling pathway through phosphorylation of Ser-180 and Ser-204 of the phosphatase. This results in dephosphorylation of c-Src. Our findings expand the current signaling model for the antiproliferative somatostatin analogue TT-232 and suggest a general interaction mechanism of PTP␣, PKC␦ and PI 3-kinase.
MATERIALS AND METHODS
Reagents, antibodies, and plasmids. Antibodies purchased were mouse monoclonal anti-PI 3-kinase (clone 93-3, Upstate Biotechnology Inc., Lake Placid, NY), mouse monoclonal anti-c-Src (Upstate Biotechnology Inc., Lake Placid, NY), monoclonal anti-HA antibody 12CA5 (Roche, Mannheim, Germany), mouse monoclonal anti-PKC␦ (Transduction Laboratories, Lexington, KY), mouse monoclonal antiphosphotyrosine (clone 4G10, Upstate Biotechnology Inc.). Polyclonal PTP␣ antibody and polyclonal p110␤ antibody were generated in our laboratory (23) . Respective secondary antibodies were obtained form Bio-Rad (Hercules, CA) and Dianova (Hamburg, Germany). For immunoblot detection, the ECL system (Amersham, Uppsala, Sweden) was used. Protein-A Sepharose was from Pharmacia Biotech. Inc. (Uppsala, Sweden). All other reagents were from Sigma (St. Louis, MO).
All cDNAs used were in CMV promoter driven expression plasmids. Mouse Erk2 cDNA (24) was fused with an N-terminal hemagglutinin (HA) epitope as described by Meloche et al. (25) . Catalytically inactive human PTP␣ where both cysteines (Cys442 and Cys732) (23) were changed to serines and serine to alanine mutant cDNAs were generated by in vitro mutagenesis. TT-232 was synthesized as described earlier (11, 12) . For treatments, a 2 mg/ml stock solution dissolved in water was used.
Cell culture and transfections. A431 and Cos-7 cells (ATCC, Manassas, VA) were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum. Cos-7 cells were transiently transfected using Lipofectamine Plus (Gibco-BRL, Rockville, MD). Transfections were made in 6-well dishes according to the manufacturer's instructions. The transfection mixtures were replaced by 10% fetal calf serum containing medium after 4 h, and 20 h later, cells were washed and starved for 24 h in serum-free medium.
Cell lysis, immunoprecipitation, and immunobloting. Prior to lysis, cells grown to 70% confluency were starved for 24 h and treated with inhibitors and agonists as indicated, washed once with PBS and lysed for 5 min on ice in buffer containing 50 mM Hepes, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 10 mM sodium-pyrophosphate, 2 mM sodium-vanadate, 10 mM sodiumfluoride, 1 mM PMSF, 10 g/ml aprotinin and 2 g/ml leupeptin. Lysates were cleaned by centrifugation at 13,000 rpm (10,000g) for 5 min at 4°C and cell lysates were precleaned with 2 g non-immune serum and 30 l protein A-Sepharose for 2 h at 4°C. Supernatants were used for immunoprecipitation using the respective antibodies and 30 l protein A-Sepharose for 4 -10 h at 4°C. Precipitates were washed three times with 0.5 ml of HNTG buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol) (26) , suspended in SDS sample buffer, boiled, subjected to gel electrophoresis and transferred to nitrocellulose in a semi-dry blotting apparatus with 0.8 mA/cm 2 current for 2 h.
PI 3-kinase assay. Endogenous PI 3-kinase was immunoprecipitated from lysates obtained from 10 cm dishes using 3 g antibody.
Immunoprecipitates were washed twice with 0.75 ml of HNTG buffer (26) and three times with 0.75 ml of Triton extraction buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 0.2 mM sodium-vanadate). Kinase reactions were performed in 50 l of kinase reaction buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 200 M adenosine, 0.5 mM MgCl 2 , 0.5 mM EGTA, 20 M ATP, 10 Ci [␥-32 P]ATP (3000 Ci/mmol)), supplemented with sonified 100 M phosphatidyl-inositol, 200 M phosphatidyl-serine in 20 mM Tris-HCl, pH 7.5 for 30 min at 30°C. Reactions were stopped with 50 l 1M HCl, phosphorylated lipid products were extracted with organic extraction and subjected to TLC. The solvent used was a mixture of chloroform/methanol/4 M NH 4 OH (9:7:2 by volume).
MAPK assay. Epitope-tagged HA-Erk2 was immunoprecipitated from lysates obtained from 6-well dishes using 2.5 g of 12CA5 antibody. Immunoprecipitates were washed three times with 0.25 ml of HNTG buffer (26) and once with 0.4 ml of MAPK kinase buffer (containing 20 mM Hepes, pH 7.5, 10 mM MgCl 2 , 1 mM DTT and 200 M sodium-vanadate). Subsequently, kinase reactions were performed in 30 l of MAPK kinase buffer supplemented with 0.5 mg/ml myelin basic protein, 50 M ATP and 1 Ci of [␥-
32 P]ATP (3000 Ci/mmol) for 10 min at room temperature. Reactions were stopped and subjected to gel electrophoresis on 15% polyacrylamide gels. Radioactivity was quantified using a Phosphoimager (Fuji).
Preparation of A431 membranes. A431 cells were washed once with buffer A (10 mM sodium-phosphate pH 7.0, 150 mM NaCl) and scraped. Cells were collected by centrifugation, resuspended in buffer B (50 mM Tris-HCl, pH 7.0, 1 mM PMSF, 10 g/ml aprotinin and 2 g/ml leupeptin) and lysed by freeze thawing in liquid nitrogen. The lysate was centrifuged at 170g for 5 min, the supernatant was subsequently centrifuged at 25,000g for 30 min. The pellet was resuspended in 200 l buffer B.
Preparation of phosphorylated poly (Glu, Tyr).
Phosphorylated poly (Glu, Tyr) (4:1) was prepared by incubating 2 mg polymer with A431 cell membranes containing 200 -500 g protein in 50 mM Hepes, pH 7.4, 0.1% Triton-X 100, 15 mM MgCl 2 , 240 M [␥-32 P]ATP, 100 M ATP, 100 M sodium-vanadate at 4°C overnight. Substrate was precipitated with TCA and dissolved in PBS.
Assay for PTP␣ activity. Prior lysis, cells grown to 90% confluence were starved for 24 h, treated with ligands and inhibitors as indicated, washed once with PBS and lysed for 5 min on ice in buffer containing 50 mM Hepes, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 10 mM sodium-fluoride, 1 mM PMSF, 10 g/ml aprotinin and 2 g/ml leupeptin. Lysates were precleaned by centrifugation at 13,000 rpm (10,000g) for 5 min at 4°C. PTP␣ was immunoprecipitated from cell lysates obtained from 10 cm dishes using 4 g of polyclonal anti-PTP␣ antibody. Immunoprecipitates were washed three times with 0.25 ml of HNTG buffer (26) and once with 0.5 ml of phosphatase buffer (50 mM Tris-HCl, pH 7.5, 10 mM DTT, 2 mM EDTA). Phosphatase reactions were performed in 50 l of phosphatase buffer supplemented with 100,000 cpm of [ 32 P]-labeled poly (Glu, Tyr) as substrate for 5 min at 30°C. The inorganic [
32 P]-phosphate liberated was extracted using the molybdate extraction procedure (27) and radioactivity was evaluated by liquid scintillation.
Phosphoamino-acid analysis. Phosphoamino-acid analysis was carried out as described previously (28) . Briefly, following gel electrophoresis and transfer onto PVDF membranes excised proteins were subjected to acid hydrolysis in 6 M HCl for 1 h. The hydrolyzed products were spotted on cellulose thin-layer chromatography plates together with a non-labeled phosphoamino-acid standard mix. Samples were separated by two-dimensional thin-layer chromatography at pH 1.9, and pH 3.5 for the first, and second dimension, respectively. Phosphoamino-acid standards were visualized with 0.25% ninhydrine in acetone, and radiolabeled products were detected by autoradiography.
RESULTS AND DISCUSSION

TT-232 Induces PI 3-Kinase Activity through a Pertussis Toxin Sensitive G-Protein
Our previous results showed that the activation of ERK/MAPK pathway by TT-232 is wortmannin sensitive (15) . Based on these findings we analyzed the effect of TT-232 on the activity of PI 3-kinase in in vitro kinase assay. In A431 cervix carcinoma cells TT-232 induced PI 3-kinase activity after 10 min (Fig. 1A) , which declined back to control levels after 60 minutes. Preincubation of A431 cells with 100 ng/ml pertussis toxin completely abolished the induction of PI 3-kinase (Fig. 1B) . These results demonstrate that PI 3-kinase activity is induced transiently in a G i/0 -protein dependent manner upon TT-232 treatment, extending our previous demonstration of a critical involvement of PI 3-kinase activity in the downstream signaling and the biological effect of TT-232 (15) .
Physical Interaction between PI3-Kinase, PTP␣, and PKC␦
The protein tyrosine-phosphatase PTP␣ was shown to be phosphorylated and activated by PKCs (18) and to regulate the activity of c-Src family members. We previously demonstrated that PKC␦ and c-Src are involved in the activation of ERK/MAPK and cell cycle arrest by TT-232 (15) . These results suggested that PTP␣ might be involved upstream of c-Src triggering the ERK/MAPK upon treatment with TT-232.
To support this hypothesis, we investigated the physical interaction of PI-3 kinase and PKC␦ with PTP␣. The phosphatase was immunoprecipitated from A431 cell lysates, blotted and probed with an antibody targeted against the 110-kDa catalytic subunit of PI-3 kinase. A 110-kDa protein band was found to coprecipitate with PTP␣ following TT-232 treatment ( Fig. 2A) .
A reciprocal experiment was carried out to confirm the association of PTP␣ with PI-3 kinase. p110 was immunoprecipitated from A431 cells and analyzed for the presence of PTP␣. Probing the membrane with PTP␣ antibody showed the association of the phosphatase and PI3-kinase in TT-232 treated cells (Fig. 2B) .
To test the assumed presence of PKC␦ in the complex, PTP␣ (Fig. 2C, upper panel) or PI3-kinase p110 (Fig. 2D, upper panel) immunoprecipitations were carried out and PKC␦ was detected with monoclonal antibody only in TT-232 treated cells.
Co-immunoprecipitation experiments with endogenously expressed PI 3-kinase and PTP␣ proteins have shown their association together with PKC␦ upon treatment with the somatostatin analogue. This indicates the formation of a signaling complex upon treatment and suggests a functional interaction between the molecules. Our findings are supported by the association of PI 3-kinase and PKC␦, which has been found upon cytokine stimulation (29) suggesting an analogous pathway. However, the protein domains involved in the interaction needs further investigations.
The Association of PTPa and PKC␦ Does Not Require the Activity of PI3-Kinase
To test the requirement of PI 3-kinase activity for the formation of the signaling complex we pretreated A431 cells with 100 nM wortmannin or 1 M Ly294002 for 15 min prior to treatment with 50 M TT-232 for 10 min. Figure 3 demonstrates that the formation of the signaling complex between PKC␦, PTP␣ and PI 3-kinase does not require the catalytic activity of PI 3-kinase. However, the activation of downstream signals does require PI 3-kinase activity. This can be explained by the involvement of yet unidentified proteins upstream of PI 3-kinase.
PTP␣ Lies Downstream of PI 3-Kinase and PKC␦ and Is Required for the Induction of Erk/MAPK
We investigated the role of PI 3-kinase and PKC inhibitors on PTP␣ activity. Cells were pretreated either with 100 nM wortmannin, or with 2.5 M GF109203X (30) prior to treatment with TT-232. Figure 4A shows that TT-232 increased PTP␣ activity up to 2.5 fold over basal level and both PI-3 kinase and PKC inhibitors abolished this effect. These findings place PTP␣ downstream of PI 3-kinase and PKC␦ in TT-232 signaling.
To study downstream events of PTP␣ activation, Cos-7 cells were transiently transfected with either wild type or a catalytically inactive mutant form of PTP␣ (C442/732S) together with hemagglutinintagged Erk2. The activity of Erk/MAPK was measured from anti-hemagglutinin immunoprecipitates (Fig.  4B) . The expression of the inactive form of PTP␣ completely abolished TT-232-induced Erk/MAPK activation. This demonstrates that the already reported activation of Erk/MAPK by TT-232 (15) is dependent on the function of PTP␣.
It has been shown that PKCs phosphorylate PTP␣ on Ser-180 and Ser-204 in vitro and in vivo upon TPA treatment and thereby induce the activity of the phos- phatase (18) . Since we had observed the requirement of PKCs for the activation of PTP␣ by TT-232 (Fig. 4A) , we tested the effect of PTP␣ Ser-180 and Ser-204 sites in the activation of Erk/MAPK in our system. Figure  4B shows that overexpression of the Ser180/204Ala double mutant of PTP␣ was sufficient to abrogate the ERK/MAPK stimulation induced by TT-232. This implies that TT-232 signaling employs the same mechanism in this part of its pathway as it has been described for TPA (18) .
To investigate the phosphorylation of PTP␣ in detail, Cos-7 cells were transiently transfected with plasmids encoding wild type, catalytically inactive PTP␣ (Cys442/732Ser) or the Ser180/204Ala double mutant followed by [
32 P]-ortho-phosphate labeling for 24 h. Cells were treated with 50 M TT-232 for 10 min, PTP␣ was immunoprecipitated with a polyclonal anti-PTP␣ antibody, and the immunoprecipitates were subjected to phosphoamino-acid analysis (Figs. 5A-5F ). Upon treatment with TT-232, serine phosphorylation of wild type PTP␣ is induced (Fig. 5B) . The increased tyrosine phosphorylation of PTP␣ is in concurrence with previous results suggesting that phosphorylation of Tyr-789 of PTP␣ by c-Src provides a potential feedback loop (17) .
TT-232 induced serine phosphorylation also of catalytically inactive PTP␣ (Figs. 5C and 5D ) meaning that the activity of PTP␣ is not required for phosphorylation. The increased tyrosine phosphorylation compared to the wild type PTP␣ is likely to be due to the lack of the autocatalytic activity of PTP␣ as reported previously (17) .
In cells overexpressing Ser180/204Ala double mutant PTP␣, no significant increase in phosphoaminoacid content was detectable upon treatment with TT-232 (Figs. 5E and 5F ). by TT-232, together with the necessity of functional PKCs for PTP␣ activation in in vitro phosphatase experiments makes us propose that these serine sites are phosphorylated by the upstream protein PKC␦ and not by other kinases.
Dephosphorylation of c-Src by PTP␣
In PTP␣-overexpressing fibroblasts, c-Src kinase is dephosphorylated at its C-terminal regulatory Tyr-527 site, which increases the activity of the kinase through the direct action of PTP␣ (20, 31) . Since we were able to demonstrate that TT-232 leads to the activation of c-Src (15), the phosphotyrosine content of c-Src upon stimulation with TT-232 was investigated in Cos-7 cells overexpressing either the wild type, or the catalytically inactive Cys442/732Ser mutant of PTP␣.
Cells were maintained in serum free medium for 16 hours prior to immunoprecipitation with c-Src antibodies. Immunoprecipitates were blotted with phosphotyrosine antibody, which revealed a double band corresponding to different phosphorylation states of c-Src: a higher band migrating at ϳ62 kDa, consistent with the stronger phosphorylated form of c-Src, and a lower band at ϳ60 kDa, likely to be corresponding to weaker phosphorylated c-Src protein. In wild type PTP␣ overexpressing Cos-7 cells, treatment with TT-232 leads to reduced intensity of the upper band, which means that c-Src is dephosphorylated. In cells carrying catalytically inactive PTP␣ this effect was blocked. Therefore, the phosphatase activity of PTP␣ is required for c-Src dephosphorylation likely by direct interaction (Fig.  6A) . To support the results, Cos-7 cells were transiently transfected either with wild type or catalytically inactive Cys442/732Ser PTP␣ together with c-Src followed by [
32 P]-ortho-phosphate labeling. Cells were treated with 50 M TT-232 for 10 min, c-Src was immunoprecipitated and the immunoprecipitates were subjected to phosphoamino-acid analysis as described above. Treatment with TT-232 resulted in dephosphorylation of c-Src tyrosine residues but did not affect the phosphorylation state of serine or threonine amino acids (Figs. 6B and 6D ). However, in cells overexpressing catalytically inactive PTP␣ dephosphorylation of tyrosine upon TT-232 treatment was not visible and the phosphoamino-acid pattern was similar to that of the untreated cells (Figs. 6C and 6E ).
These observations strengthen our hypothesis that the catalytic activity of PTP␣ is required for the dephosphorylation and thus activation of c-Src upon treatment with the somatostatin analogue. They are concordant with the understanding of c-Src regulation by PTP␣ proposed by Zheng et al. (31) . Therefore, this is likely that the activation of c-Src by dephosphorylation of the regulatory Tyr-527 site by PTP␣ is the mechanism of the activation of the MAPK pathway reported previously (15) .
We propose a model where the treatment with TT-232 through somatostatin receptor 1 induces the formation of a signaling complex composed of PI 3-kinase, PTP␣ and PKC␦. The activation of PI 3-kinase through G i/o enhances PKC␦ activity which in turn phosphorylates Ser180 and Ser204 of PTP␣. This leads to the activation of the tyrosine phosphatase that dephosphorylates its major substrate c-Src at the inhibitory Tyr-527. The increased activity of c-Src mediates the signal to the Erk/MAPK pathway (Fig. 7) . The activation of the proposed signaling cascade has been demonstrated to play a crucial role in the G 1 -to-S phase arrest induced by TT-232 (15) . The results reported here expand our concept of the mechanism of Erk activation by TT-232. Since Erk 32 P]-ortho-phosphate labeling. Cells were treated with 50 M TT-232 and c-Src was immunoprecipitated. The radiolabeled bands were excised and subjected to phosphoamino-acid analysis as described above.
FIG. 7.
Model of the TT-232 induced signaling complex. Gray box shows the physical interaction between the proteins. activation seems to be required for cell cycle arrest induced by somatostatin and somatostatin analogues, we conclude that the formation of this signaling complex and its functional integrity is necessary for the observed biological effect. Apart from shedding light on the cellular events mediated by the anti-cancer drug TT-232, our results are of great interest to understand the signaling mechanisms of somatostatin and somatostatin analogues as well as of the regulation mechanisms of PKCs and PTP␣.
